Heartbeat.Bio

HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure

7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal mapping of the genome for target discovery with HeartBeat.bio’s human-based Cardioid Drug Discovery Platform to drive innovation in heart failure drug development. Under the agreement,...
Vienna Biocenter 6 Dr. Bohr-Gasse 7 A-1030 Vienna Austria